Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 7/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522702 | 0.80 | TSHR (0.53) | TSHRL3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL27653618 | 0.79 | TSHR (0.51) | TSHRL3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL1656235 | 0.79 | ESR1 (0.40) | ABCB1TSHRL3MBTL1TDP1POLB | |
| SCHEMBL523596 | 0.78 | TSHR (0.50) | TSHRL3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL521966 | 0.78 | EGLN1 (0.50) | TSHRL3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL522481 | 0.78 | MAPT (0.48) | TSHRL3MBTL1TDP1POLBALDH1A1 | |
| SCHEMBL27941879 | 0.78 | TSHR (0.45) | ABCB1TSHRL3MBTL1TDP1POLB | |
| SCHEMBL1656236 | 0.78 | TSHR (0.38) | ABCB1TSHRL3MBTL1TDP1POLB | |
| SCHEMBL523470 | 0.78 | EGLN1 (0.43) | ABCB1TSHRL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL524667 | 0.78 | EGLN2 (0.41) | ABCB1TSHRL3MBTL1TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9339527-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2016-01-14 | — | — | US | disclosed |
| US-9174976-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2044028-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | disclosed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007090068-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | ABCB1 3380/4885TSHR 3855/4885L3MBTL1 1352/4885 |
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | ABCB1 1636/4885TSHR 3728/4885L3MBTL1 3805/4885 |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ABCB1 3890/4885TSHR 3882/4885L3MBTL1 1876/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ABCB1 3890/4885TSHR 3882/4885L3MBTL1 1876/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | ABCB1 3380/4885TSHR 3855/4885L3MBTL1 1352/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ABCB1 3890/4885TSHR 3882/4885L3MBTL1 1876/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | ABCB1 3380/4885TSHR 3855/4885L3MBTL1 1352/4885 |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | ABCB1 2472/4885TSHR 3818/4885L3MBTL1 2975/4885 |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN2, HIF1A | ABCB1 3686/4885TSHR 3716/4885L3MBTL1 1913/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | ABCB1 1978/4885TSHR 1302/4885L3MBTL1 4281/4885 |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | ABCB1 2472/4885TSHR 3818/4885L3MBTL1 2975/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | ABCB1 4325/4885TSHR 3288/4885L3MBTL1 514/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | ABCB1 1706/4885TSHR 1016/4885L3MBTL1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.